miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.

These data confirm that there may be significant benefit in combining Nutlin-3a, cytarabine, and miR-10a inhibition in miR-10a-overexpressing AML cells, potentially allowing increased efficacy and/or decreased dosage and therefore toxicity while maintaining equivalent anti-leukemic activity. miR-10a regulates the p53-mediated switch between autophagy and apoptosis Activation of the p53/Rb-mediated stress response is potentiated by increased expression of miR-10a target RBCC1 via its direct binding to and stabilization of p53, and subsequent upregulation of Rb, p16, and p21 [ 25 ].

also in 13,097 other papers